Skip to main content
Medical information Clinical review pending

Genetic Testing

OncoPro NCCN Lung Cancer Panel Test

The OncoPro NCCN Lung Cancer Panel Test uses advanced genetic sequencing to detect key mutations in lung cancer, aiding in personalized treatment decisions. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
20 mL whole blood collected in 2 Streck tubes.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is included with the sample.
Test priceKSh 234,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the OncoPro NCCN Lung Cancer Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with suspected lung cancer based on symptoms or imaging.
  • ✓Individuals with a confirmed diagnosis of lung cancer.
  • ✓Patients seeking personalized treatment options based on tumor genetics.
  • ✓Individuals with a family history of lung cancer.
  • ✓Patients considering participation in clinical trials for lung cancer.
02

In plain language

What this test helps you understand

Identifies specific genetic mutations in lung cancer tissue or blood to guide personalized treatment strategies, predict response to targeted therapies, and inform clinical trial eligibility.
The OncoPro NCCN Lung Cancer Panel Test is a diagnostic tool designed to detect genetic mutations associated with lung cancer. It utilizes Next Generation Sequencing technology to analyze specific genetic alterations that can influence treatment choices and patient outcomes. Early and accurate diagnosis is important for managing lung cancer.

This comprehensive panel looks for several key genetic alterations linked to lung cancer, including EGFR, ALK, ERBB2, BRAF, MET, RET, ROS1, NTRK1, KRAS, and MSI.

Individuals who might benefit from this test include those experiencing lung cancer symptoms like a persistent cough, chest pain, or unexplained weight loss, people with a family history of lung cancer or other risk factors, and patients already diagnosed with lung cancer who need help determining the most effective treatment based on their cancer's genetic profile.

Taking this test can help identify specific genetic mutations that guide treatment decisions, enable personalized therapy based on an individual's genetic makeup, detect potential treatment resistance early, and provide access to relevant clinical trials.

Discussing the results with your oncologist is crucial for understanding their implications and determining the best course of action based on your genetic profile.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is included with the sample.
Sample20 mL whole blood collected in 2 Streck tubes.
MethodologyNext Generation Sequencing (NGS)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations but may not identify all possible genetic alterations. Results should be interpreted in the context of the patient's clinical presentation and other diagnostic findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test uses advanced genetic sequencing to detect key mutations associated with lung cancer, helping guide personalized treatment decisions.
Patients with suspected or confirmed lung cancer, those seeking personalized treatment, and individuals with relevant risk factors may benefit.
The test requires 20 mL of whole blood collected in 2 Streck tubes.
Confirm with the laboratory before booking.
Results should be discussed with your oncologist to understand their implications for your specific situation and treatment plan.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp